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I thank the society and its Education Committee for the
ASHG 2006 Award for Excellence in Genetics Education.
I greatly appreciate this honor.
This award focuses around my work on the GeneTests
project (http://www.genetests.org/), an information re-
source for health care providers to help integrate genetic
services into patient care. GeneTests is located at the Uni-
versity of Washington, Seattle, and is funded by a contract
from the National Institutes of Health. We are particularly
grateful to the National Library of Medicine (NLM), Na-
tional Human Genome Research Institute (NHGRI), and
the National Cancer Institute (NCI) for their continuous
support of GeneTests since its inception in 1992.
GeneTests comprises four sections:
1. GeneReviews, which serve as the user’s manual for
genetic testing for specific diseases. Currently, over
360 GeneReviews are posted on the Web site. One
new GeneReview is added each week.
2. The Laboratory Directory, which serves as the “Yel-
low Pages” of genetics laboratories. Currently, over
600 clinical and research laboratories list information
on tests for about 1,225 inherited diseases. Of these,
approximately 930 are clinical tests, and approximate-
ly 295 are research-only tests.
3. The Clinic Directory, which serves as the “Yellow
Pages” of genetics clinics. Currently, over 1,100 clin-
ics are listed, providing services in pediatric and adult
genetics, biochemical genetics, cancer genetic coun-
seling and risk assessment, prenatal diagnosis, and
preimplantation genetic diagnosis.
4. Educational Materials, which include an illustrated
glossary of genetic counseling and testing terms. Over
200 illustrations provide graphics and case vignettes,
to familiarize nongeneticist health care providers
with these terms that are integral to our work as ge-
netics professionals.
GeneTests has focused on molecular genetic testing for
inherited disorders, because
1. The test menu is ever changing, as new genes are
discovered and new test methods are introduced to
improve mutation detection rates,
2. There are many laboratories, each testing for a few
diseases, and
3. Molecular genetic tests can be used, not only in a
traditional paradigm for diagnosis and predictive
testing when treatment is available, but also in an
untraditional paradigm of personal decision making
(i.e., predictive testing when no treatment is avail-
able, carrier testing for autosomal recessive or X-
linked disorders, prenatal diagnosis, and preimplan-
tation genetic diagnosis).
In its goal to integrate genetic services into patient care,
GeneTests has relied on the expertise and good will of
collaborators and users around the globe. Over 800 inter-
national expert-authors have written over 360 GeneRe-
views. Sixty-two percent of authors are from the United
States and 38% from other countries. Authors receive no
financial compensation and must adhere to GeneReviews
format and style and respond to internal and external peer
review. Authors agree to serve for a 2-year term of author-
ship, during which they revise their entries when test
availability or methods change, and they update the entry
every 2 years in a formal, comprehensive process. Those
who serve as reviewers for each GeneReview also receive
no financial compensation. They are asked to review each
entry for accuracy, currency, and suitability for health care
providers.
The GeneTests Laboratory Directory has grown contin-
uously. In 2001, about 500 laboratories were listed, of
which 76% were from the U.S. and 24% were from other
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Figure 1. Naming hierarchy for APC-associated polyposis conditions
Figure 2. Naming hierarchy for FMR1-related disorders
countries. Currently, in 2006, 642 laboratories are listed,
64% from the U.S. and 36% from other countries.
The educational issues that GeneTests’ staff, authors,
and reviewers have identified are many. One example is
familiarizing others with the unique vocabulary of med-
ical genetics. We know that geneticists “talk funny,” but
we also have to ask ourselves if we are being as clear as
possible when trying to communicate information about
genetic diseases and genetic tests. For example, what are
we really saying when we use the terms “sporadic” and
“simplex”? These are quite different terms and have dif-
ferent recurrence-risk implications. “Sporadic” refers to a
chance event. “Simplex” refers to a single occurrence of
a condition in a family. We geneticists know that simplex
cases can result from autosomal recessive inheritance, X-
linked inheritance, and autosomal dominant inheritance,
caused by either a de novo mutation or reduced pene-
trance. Furthermore, nongenetic causes of a simplex case
can include alternate paternity or adoption. Thus, we in
the genetics community need to be very clear when we
use the term “sporadic” that it is a chance event with little
risk of recurrence and that when we use the term “sim-
plex,” risk of occurrence in relatives remains a possibility.
Another educational issue is disease naming. Because of
new gene discoveries, gene-based lumping and splitting
of phenotypes is a daily occurrence. We may find ourselves
in the dilemma of trying to figure out “What disease is
this?” From the laboratory perspective, testing detects al-
terations in a gene, not a phenotype. From the clinician’s
perspective, patients present with altered phenotypes. A
disease name must relate to genes for laboratories and to
phenotypes for clinicians. Furthermore, disease naming
has become more of a process than a static phenomenon.
Often, in naming a disease (phenotype) before the caus-
ative gene(s) is known, the phenotype is defined narrowly,
in order to reduce heterogeneity and facilitate gene dis-
covery. However, after the causative gene is discovered,
the phenotypic spectrum typically expands as patients are
tested. Understanding of the broadest aspects of the phe-
notypic range is essential to patient care and genetic coun-
seling of at-risk relatives. Using familial adenomatous po-
lyposis (FAP) as an example, the following can be said
about naming. Before the causative gene was known, the
phenotype was narrowly defined; however, once the APC
gene was discovered, it became apparent that the spec-
trum of APC-associated polyposis conditions included at-
tenuated FAP at the mild end of the spectrum and Gardner
syndrome and Turcot syndrome at the more severe end
of the spectrum.
To relate information about the altered gene and its as-
sociated phenotypes, the GeneTests staff developed a nam-
ing-hierarchy convention in which the spectrum of disor-
ders caused by mutation in a given gene is designated“gene-
related condition” (e.g., APC-associated polyposis condi-
tions). Its “children” then become the associated phe-
notypes (fig. 1). In this way, information about testing can
be linked to the name “APC-associated polyposis condi-
tions,” and the phenotypes (children) are listed under it,
so that clinicians who have searched on one of those terms
will see that term in correct relationship to information
on the altered gene and other associated phenotypes.
Another example of this naming hierarchy is fragile X
syndrome (fig. 2). Initially, the GeneTests database had
stand-alone information on fragile X syndrome. However,
over the past several years, continuing clinical investiga-
tions resulted in broader understanding of the phenotypes
associated with mutations in FMR1, leading to creation of
the hierarchy “FMR1-related disorders,” with fragile X syn-
drome, FMR1-related premature ovarian failure, and frag-
ile X-associated tremor/ataxia syndrome as its phenotypic
children.
Finally, the GeneTests staff would like your help in im-
proving GeneTests. We would like you to contact us so
that we can correct errors, hear your ideas on how to im-
prove the site, and explore potential collaborations. We
would like you to refer new laboratories and clinics to be
listed in GeneTests and new users to the information con-
tained on the Web site. We are hoping that disease experts
will consider volunteering to write a GeneReview. We
would welcome working with you if you would like to
assign a student to conduct a project that in some way
touches on GeneTests.
Thank you from the Directories staff: Gina McCullough
Grohs, Laboratory Directory Coordinator; Clinic Directory
staff; Roberto Spiro, M.S., Genetic Counselor; and Kathi
Marymee, M.S., Genetic Counselor and Resources Liaison;
GeneReviews Editorial staff: Cynthia R. Dolan, M.S., Ge-
netic Counselor, Associate Editor; Thomas D. Bird, M.D.,
Associate Editor; Gerald L. Feldman, M.D., Ph.D., Associate
Editor; Karen Stephens, Ph.D., Associate Editor; Suzanne B.
Cassidy, M.D., Assistant Editor; and Mary Beth P. Dinolus,
M.D., Assistant Editor; GeneReviews Production team:
Monica Smersh, Managing Editor; Miriam Espeseth, M.A.,
Online Production Editor; Cynthia Abair, M.A., Graphics
Editor; and Carla Gifford, Editorial Assistant; and Informa-
tion Technology staff: Sergey Mikhaylov, M.S., Database Ad-
ministrator; and Brad Willson, Systems Administrator.
Thank you for this honor.
